

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. An aqueous virucidal formulation (based on %w/v of the total formulation) comprising:
 - (a) about 0.10% to about 1.25% w/v PVP-I;
 - (b) 0.00% to about 15% w/v of hyaluronic acid, polyethylene glycol and/or glycerol;
 - (c) 0.00% to about 0.20% w/v of menthol;
 - (d) 0.00% to about 30% of a polar solvent;
 - (e) 0.00% to about 5% of sodium hydrogen phosphate or similar buffer; and
 - (f) 0.00% to about 0.20% w/v of iodide and/or iodate salt;wherein the formulation comprises at least two of (b) – (f).
2. An aqueous virucidal formulation according to claim 1 comprising:
 - (a) about 0.10% to about 1.25% w/v PVP-I;
 - (b) about 0.005% to about 0.20% w/v of iodide and/or iodate salt; and
 - (c) about 0.005% to about 0.05% w/v menthol.
3. An aqueous virucidal formulation according to claim 1 or claim 2 comprising:
 - (a) about 0.10% to about 1.25% w/v PVP-I;
 - (b) about 0.005% to about 0.01% w/v of an iodate salt;
 - (c) about 0.005% to about 0.05% w/v menthol;
 - (d) about 0.005% to about 0.10% w/v of an iodide salt; and
 - (e) about 1.0% w/v to about 15% w/v of glycerol.
4. An aqueous virucidal formulation according to any one of claims 1 to 3 comprising:
 - (a) about 0.10% to about 1.25% w/v PVP-I;
 - (b) about 0.005% to about 0.01% w/v of an iodate salt;
 - (c) about 0.005% to about 0.05% w/v menthol;
 - (d) about 0.005% to about 0.10% w/v of an iodide salt;
 - (e) about 1.0% w/v to about 15% w/v of glycerol; and
 - (f) about 0.2% w/v to about 30% w/v of a polar solvent other than water.

5. An aqueous virucidal formulation according to any one of claims 1 to 4 comprising:
 - (a) about 0.10% to about 1.0% w/v PVP-I;
 - (b) about 0.005% to about 0.01% w/v of an iodate salt;
 - (c) about 0.005% to about 0.05% w/v menthol;
 - (d) about 0.005% to about 0.10% w/v of an iodide salt;
 - (e) about 1.0% w/v to about 10% w/v of glycerol;
 - (f) about 0.2% w/v to about 1.0% w/v of a polar solvent other than water
 - (g) about 0.05% to about 0.20% w/v of sodium dihydrogen phosphate dihydrate;
 - (h) sodium hydroxide q.s. ; and
 - (i) water q.s..
6. An aqueous virucidal formulation according to anyone of claims 1 to 5 wherein the concentration of PVP-I is about 0.25% to about 1.00%.
7. An aqueous virucidal formulation according to claim 5 wherein the concentration of PVP-I is about 0.50%.
8. An aqueous virucidal formulation according to any one of claims 5 to 7 wherein the polar solvent other than water is ethanol.
9. An aqueous virucidal formulation according to anyone of claims 1 to 8 wherein the pH of the formulation is about 3 to about 6.
10. A method of treating viral infection in a subject comprising administering to the subject an effective amount of the aqueous virucidal formulation according to any one of claims 1 to 9.
11. A method according to claim 10 wherein the formulation is administered intranasally.
12. A method of reducing the volume of mucous secreted, or reducing the activity, viability or number of viruses contained in secreted mucous, or reducing the period during which virus-laden mucous is present, and thereby reducing the risk of viruses migrating to secondary sites in the respiratory tract to establish or contribute to secondary illnesses, including the step of administering to a subject an effective amount of an aqueous virucidal formulation according to any one of claims 1 to 9.

13. The method according to claim 12 wherein the secondary illness is a respiratory tract infection.
14. The method according to claim 13 wherein the secondary illness selected from the group selected from sinusitis, bronchitis and otitis media.
15. A method according to anyone of claims 10 to 14 wherein the aqueous virucidal formulation is administered nasally at a temperature of between 10° to 35°C.